BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

899 related articles for article (PubMed ID: 10630955)

  • 1. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role.
    Steinberg JL; Yeo W; Zhong S; Chan JY; Tam JS; Chan PK; Leung NW; Johnson PJ
    J Med Virol; 2000 Mar; 60(3):249-55. PubMed ID: 10630955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B virus reactivation in patients receiving chemotherapy for malignancies: role of precore stop-codon and basic core promoter mutations.
    Alexopoulou A; Theodorou M; Dourakis SP; Karayiannis P; Sagkana E; Papanikolopoulos K; Archimandritis AJ
    J Viral Hepat; 2006 Sep; 13(9):591-6. PubMed ID: 16907845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequence variations of precore/core and precore promoter regions of hepatitis B virus in patients with or without viral reactivation during cytotoxic chemotherapy.
    Yeo W; Zhong S; Chan PK; Ho WM; Wong HT; Chan AS; Johnson PJ
    J Viral Hepat; 2000 Nov; 7(6):448-58. PubMed ID: 11115057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study.
    Yeo W; Chan PK; Hui P; Ho WM; Lam KC; Kwan WH; Zhong S; Johnson PJ
    J Med Virol; 2003 Aug; 70(4):553-61. PubMed ID: 12794717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration.
    Dai MS; Wu PF; Shyu RY; Lu JJ; Chao TY
    Liver Int; 2004 Dec; 24(6):540-6. PubMed ID: 15566502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy.
    Kuwahara R; Kumashiro R; Murashima S; Ogata K; Tanaka K; Hisamochi A; Hino T; Ide T; Tanaka E; Koga Y; Sata M
    J Med Virol; 2004 Jan; 72(1):26-34. PubMed ID: 14635007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The prevalence and clinical significance of precore and core promoter mutations in Korean patients with chronic hepatitis B virus infection].
    Kim HJ; Yoo BC
    Taehan Kan Hakhoe Chi; 2002 Jun; 8(2):149-56. PubMed ID: 12499800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy.
    Cho SW; Hahm KB; Kim JH
    Hepatology; 2000 Nov; 32(5):1163-9. PubMed ID: 11050070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in the hepatitis B virus precore/core gene and core promoter in patients with severe recurrent disease following liver transplantation.
    McMillan JS; Bowden DS; Angus PW; McCaughan GW; Locarnini SA
    Hepatology; 1996 Dec; 24(6):1371-8. PubMed ID: 8938164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low frequency of precore hepatitis B virus mutants in anti-hepatitis B e-positive reactivation after loss of hepatitis B e antigen in patients with chronic hepatitis B.
    Loriot MA; Marcellin P; Talbodec N; Guigonis V; Gigou M; Boyer N; Bezeaud A; Erlinger S; Benhamou JP
    Hepatology; 1995 Mar; 21(3):627-31. PubMed ID: 7875659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection.
    Ahmed A; Keeffe EB
    Am J Gastroenterol; 1999 Jan; 94(1):249-51. PubMed ID: 9934765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience.
    Huang H; Cai Q; Lin T; Lin X; Liu Y; Gao Y; Peng R
    Expert Opin Pharmacother; 2009 Oct; 10(15):2399-406. PubMed ID: 19761353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene heterogeneity of hepatitis B virus isolates from patients with severe hepatitis B.
    Wu W; Chen Y; Ruan B; Li LJ
    Hepatobiliary Pancreat Dis Int; 2005 Nov; 4(4):530-4. PubMed ID: 16286257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations.
    Picardi M; Pane F; Quintarelli C; De Renzo A; Del Giudice A; De Divitiis B; Persico M; Ciancia R; Salvatore F; Rotoli B
    Haematologica; 2003 Nov; 88(11):1296-303. PubMed ID: 14607759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer.
    Borentain P; Colson P; Coso D; Bories E; Charbonnier A; Stoppa AM; Auran T; Loundou A; Motte A; Ressiot E; Norguet E; Chabannon C; Bouabdallah R; Tamalet C; GĂ©rolami R
    J Viral Hepat; 2010 Nov; 17(11):807-15. PubMed ID: 20002298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection.
    Chan HL; Tsang SW; Liew CT; Tse CH; Wong ML; Ching JY; Leung NW; Tam JS; Sung JJ
    Am J Gastroenterol; 2002 Feb; 97(2):406-12. PubMed ID: 11866280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of mutations in the enhancer 2/core promoter region of hepatitis B virus in patients with chronic hepatitis B virus infection: comparison with mutations in precore and core regions in relation to clinical status.
    Honda A; Yokosuka O; Ehata T; Tagawa M; Imazeki F; Saisho H
    J Med Virol; 1999 Apr; 57(4):337-44. PubMed ID: 10089043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy.
    Shin JW; Chung YH; Choi MH; Kim JA; Ryu SH; Jang MK; Kim IS; Park NH; Lee HC; Lee YS; Suh DJ
    J Gastroenterol Hepatol; 2005 Jun; 20(6):844-9. PubMed ID: 15946130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in the core promoter region of hepatitis B virus in patients with chronic hepatitis B.
    Kurosaki M; Enomoto N; Asahina Y; Sakuma I; Ikeda T; Tozuka S; Izumi N; Marumo F; Sato C
    J Med Virol; 1996 Jun; 49(2):115-23. PubMed ID: 8991934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of carriers of hepatitis B virus from a tertiary referral hospital: does the viral load change during the natural course of infection?
    Aakanksha ; Asim M; Sharma PK; Das BC; Kar P
    J Med Virol; 2011 Jul; 83(7):1151-8. PubMed ID: 21520137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.